Skip to main content
Clinical Trials/NCT04512807
NCT04512807UnknownNot Applicable

Low Anti-mullerian Hormone and Pregnancy Outcome in IVF

Al Baraka Fertility Hospital0 sites650 target enrollmentStarted: October 15, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
650
Primary Endpoint
clinical pregnancy rate

Study Overview

Brief Summary

Anti-Mu¨llerian hormone (AMH) is an established marker of ovarian reserve (La Marca et al., 2010; Nelson et al., 2009) and predicts both high and low responses in ovarian stimulation cycles (Eldar-Geva et al., 2005; Nardo et al., 2009; Nelson et al., 2007). Presently, AMH helps clinicians counsel patients prior to IVF treatment (La Marca et al., 2011), despite the fact that it fails to predict who will become pregnant (Lamazou et al., 2011; Riggs et al., 2011). It has been demonstrated that poor responders can achieve both pregnancy and live birth (Weghofer et al., 2011). There are few studies regarding extremely low AMH concentrations and live births (Fraisse et al., 2008; Tocci et al., 2009; Weghofer et al., 2011) and they present either a small number of patients or limited data describing the groups of investigated patients. Another factor affecting pregnancy rates is endometriosis, a chronic gynaecological disease characterized by the presence of functional endometrial tissue outside the uterine cavity (Koninckx et al., 1991). Many studies have reported that pregnancy rates are lower in women with endometriosis than in controls (Gupta et al., 2008; Koninckx et al., 1991 Pellicer et al., 2000). Lower AMH serum concentrations are associated with endometriosis severity (Shebl et al., 2006). The primary objective of the present study was to assess the clinical pregnancy rates in women with extremely low AMH concentrations with respect to age.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
22 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Women ≥22 years age AMH is 0.5 and less Body mass index- 18.5-30 kg/m 2 The normal uterine cavity on ultrasound scan At least one good quality embryo present for transfer Women willing to comply with the clinical study protocol

Exclusion Criteria

  • Women ≥ 45 years age
  • AMH >0.5
  • Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis)
  • Endocrine dysfunction or organ dysfunction such as liver or kidney failure.

Outcomes

Primary Outcomes

clinical pregnancy rate

Time Frame: 4 weeks

fetal heart activity

pregnancy test

Time Frame: 2 weeks

B-HCG

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Al Baraka Fertility Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Kamal Rageh

doctor , medical director

Al Baraka Fertility Hospital

Similar Trials